Durvalumab and Guadecitabine in Advanced Clear Cell Renal Cell Carcinoma: Results from the Phase Ib/II Study BTCRC-GU16-043

Patients received guadecitabine with durvalumab. The study enrolled 57 patients, six in Phase Ib with safety being the primary objective and 51 in Phase II, comprising 2 cohorts.
[Nature Communications]
Full Article